Aurora Cannabis Inc. Earnings Recaps
Shares rose 6% on stronger-than-expected international medical cannabis revenue growth and solid margin expansion, driven by leadership in Germany and the accretive acquisition of EU GMP-certified manufacturing capacity.
Key takeaways
- International medical cannabis net revenue increased 17% to $43 million, representing 64% of total net revenue, up from 50% a year ago.
- Adjusted gross margin reached 58%, at the high end of the expected annual range, supported by strong contributions from international markets.
- Acquisition of Safari Flower Company, with its EU GMP-certified 59,000 square foot facility, added critical manufacturing capacity and was accretive to adjusted EBITDA.
- Germany remains the largest and fastest-growing market, with Aurora maintaining premium and core segment leadership despite pricing pressure and increased competition.
- The company ended the quarter with nearly $150 million in cash, no debt, and ongoing investments to expand EU GMP production capacity and improve yields through plant science.
Shares dropped 7.6% on concerns over intensifying pricing pressure in international markets and the planned exit from lower-margin Canadian consumer segments, signaling investor skepticism about near-term margin sustainability and strategic trade-offs.
Key takeaways
- Net revenue rose 11% to CAD 321 million, driven by double-digit growth in global medical cannabis and exceeding guidance by CAD 8 million.
- Adjusted gross margin improved to 64%, reflecting operational efficiencies and scientific investments, although industry-wide competitive pressures are increasing.
- Adjusted EBITDA grew 32% year-over-year, reaching CAD 54 million, supported by disciplined cost management.
- The company initiated a strategic exit from lower-margin Canadian consumer markets, generating one-time cash impacts, while focusing on higher-margin global medical cannabis.
- Acquisition of Safari Flower Company expands EU GMP capacity by 40%, expected to contribute positively to adjusted EBITDA from FY 2027 onward.
Aurora Cannabis Inc. delivered a strong Q3 2026 performance with a 7% increase in net revenue, driven primarily by robust international medical cannabis growth. The company reported positive free cash flow and improved margins while focusing on strategic market exits to enhance profitability.
Key takeaways
- Net revenue increased by 7%, with a 12% rise in global medical cannabis sales, surpassing expectations.
- Adjusted gross margin improved to 62%, supported by a strong international performance with medical cannabis margins at 69%.
- Achieved positive adjusted EBITDA of $18.5 million and free cash flow of $15.5 million, maintaining a solid balance sheet with over $150 million in cash.
- Initiating exits from lower-margin Canadian consumer cannabis markets to concentrate resources on higher-margin global medical cannabis growth.
- Announced a new at-the-market equity program to raise up to $100 million for strategic investments including cultivation capacity enhancements.